Trxade Group is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 11,800+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services.
Company profile
Ticker
MEDS
Exchange
Website
CEO
Surendra Kumar Ajjarapu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Bluebird Exploration Co., TRXADE GROUP, INC., XCELLINK INTERNATIONAL INC.
SEC CIK
Corporate docs
Subsidiaries
Trxade, Inc. • Integra Pharma Solutions, Inc. • Community Specialty Pharmacy, LLC • Alliance Pharma Solutions, LLC • Bonum Health, LLC • MedCheks, LLC • SOSRx LLC ...
MEDS stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
23 Jan 23
8-K
Departure of Directors or Certain Officers
20 Jan 23
8-K
Departure of Directors or Certain Officers
5 Jan 23
8-K
Submission of Matters to a Vote of Security Holders
21 Dec 22
8-K
Departure of Directors or Certain Officers
16 Dec 22
424B3
Prospectus supplement
8 Dec 22
EFFECT
Notice of effectiveness
5 Dec 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Dec 22
CORRESP
Correspondence with SEC
30 Nov 22
UPLOAD
Letter from SEC
30 Nov 22
Transcripts
MEDS
Earnings call transcript
2022 Q3
8 Nov 22
MEDS
Earnings call transcript
2022 Q2
26 Jul 22
MEDS
Earnings call transcript
2022 Q1
10 May 22
MEDS
Earnings call transcript
2021 Q4
29 Mar 22
MEDS
Earnings call transcript
2021 Q3
26 Oct 21
MEDS
Earnings call transcript
2021 Q2
27 Jul 21
MEDS
Earnings call transcript
2021 Q1
27 Apr 21
MEDS
Earnings call transcript
2020 Q4
30 Mar 21
MEDS
Earnings call transcript
2020 Q3
26 Oct 20
Latest ownership filings
4
MICHAEL L PETERSON
20 Jan 23
3
MICHAEL L PETERSON
6 Jan 23
4
A. Jeffrey Newell
30 Dec 22
SC 13D/A
AJJARAPU SURENDRA K
19 Oct 22
SC 13D/A
Patel Prashant
19 Oct 22
3
A. Jeffrey Newell
14 Oct 22
4
Prashant Patel
16 Sep 22
4
Janet Huffman
16 Sep 22
4
Donald G. Fell
16 Sep 22
4
CHARLES L POPE
16 Sep 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 321.72 k | 321.72 k | 321.72 k | 321.72 k | 321.72 k | 321.72 k |
| Cash burn (monthly) | 213.50 k | 270.85 k | 135.68 k | 271.75 k | 192.31 k | 265.22 k |
| Cash used (since last report) | 834.51 k | 1.06 mm | 530.31 k | 1.06 mm | 751.66 k | 1.04 mm |
| Cash remaining | -512.79 k | -736.93 k | -208.60 k | -740.46 k | -429.95 k | -714.95 k |
| Runway (months of cash) | -2.4 | -2.7 | -1.5 | -2.7 | -2.2 | -2.7 |
Institutional ownership, Q3 2022
6.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 13 |
| Opened positions | 1 |
| Closed positions | 2 |
| Increased positions | 3 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 658.00 k |
| Total shares | 579.33 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Ridgewood Investments | 200.60 k | $227.00 k |
| Vanguard | 179.27 k | $203.00 k |
| National Asset Management | 85.14 k | $97.00 k |
| Geode Capital Management | 42.06 k | $47.00 k |
| Wealth Dimensions | 30.98 k | $35.00 k |
| Two Sigma Securities | 14.97 k | $17.00 k |
| Tower Research Capital | 9.05 k | $10.00 k |
| Thrivent Trust Co of Tennessee | 5.35 k | $9.00 k |
| Advisor | 4.55 k | $5.00 k |
| UBS UBS Group AG - Registered Shares | 3.84 k | $4.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Jan 23 | Peterson Michael L | Common stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 118,940 |
| 16 Jan 23 | Peterson Michael L | Stock Option Common Stock | Grant | Acquire A | No | No | 0 | 135,802 | 0.00 | 135,802 |
| 30 Dec 22 | A. Jeffrey Newell | Common stock | Grant | Acquire A | No | No | 0 | 79,062 | 0.00 | 79,062 |
| 1 Sep 22 | Ajjarapu Surendra K | Common stock | Grant | Acquire A | No | No | 0 | 51,724 | 0.00 | 1,164,240 |
News
Why Panbela Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
26 Jan 23
12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session
26 Jan 23
12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session
19 Jan 23
12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session
18 Jan 23
12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session
13 Jan 23